J&J submits FDA application for myasthenia gravis drug nipocalimab
by
Contributor since / Followers
Contributor since / Followers
1 month ago
Iryna Drozd
- Johnson & Johnson (NYSE:JNJ) said that it has submitted a Biologics License Application (BLA) to the FDA for its drug candidate nipocalimab for the treatment of generalized myasthenia gravis, or gMG.
- The pharmaceutical giant said it was the first global submission for the therapy, according to a statement.
- Argenx (ARGX), UCB and AstraZeneca (AZN) already have drugs on the market to treat MG, a rare autoimmune disease that causes profound muscle weakness and extreme fatigue.
- Other companies working on treatments for the condition include Roche (OTCQX:RHHBY), Alnylam (ALNY), Regeneron (REGN), Dianthus Therapeutics (DNTH), Cartesian Therapeutics (RNAC), Amgen (AMGN) and Immunovant (IMVT).